DRL-Header DRL-Header

X

Find Oncology Drugs in Phase I/II Clinical Development in TAIWAN

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

            Lead Product(s): Silmitasertib

            Therapeutic Area: Oncology Product Name: CX-4945

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Pediatric Brain Tumor Consortium

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 17, 2021

            Details:

            Senhwa’s clinical partner, the Pediatric Brain Tumor Consortium, is currently conducting a Phase I/II and Surgical Study of Silmitasertib in both children and adults with recurrent SHH Medulloblastoma.